Navigation Links
Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization
Date:7/2/2010

(WASHINGTON, July 1, 2010) Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society. Treatment for HL typically includes the drug doxorubicin as part of chemotherapy and may also include radiation therapy to lymph nodes in the chest. Although treatment produces high cure rates, these treatments can also be toxic to the heart. This makes treating patients with pre-existing heart disease particularly challenging.

To evaluate the toxicity of HL treatment, researchers collected data on hospitalizations for heart disease among 1,096 HL patients who had received common treatment regimens, including doxorubicin-containing chemotherapy and radiation therapy to lymph nodes in the chest.

The study found that the toxicity of different treatments varied significantly depending on whether patients had pre-existing heart disease. In particular, radiation therapy to the chest appeared to increase the risk of cardiac hospitalization to a much greater degree among those with pre-existing heart disease than among those without. Also, patients with heart disease whose treatment included radiation therapy to the chest were found to be approximately 2.5 times more likely to be hospitalized for cardiac reasons than those who were treated with chemotherapy alone.

"Efforts to reduce cardiac exposure to radiation in patients with pre-existing cardiac disease are warranted based on these findings," said David Hodgson, MD, David Hodgson, radiation oncologist at the Princess Margaret Hospital Cancer Program, University Health Network, investigator at the Institute of Clinical Evaluative Sciences, Ontario, Canada, and senior author of the study. "However, the lower cardiac complication rate among patients treated only with chemotherapy occurred in part because they were more likely to die of other causes, so it is not a simple message that chemotherapy alone is better for all patients. Clinical trials are ongoing to more accurately identify which patients benefit from radiation therapy and to further reduce the administered dose to normal tissues," Hodgson said. "But oncologists need to be be aware of their patients' heart health and vigilant about post-treatment monitoring and active intervention to reduce their patients' cardiac risk factors."

Possible explanations for this relationship have been cited in animal studies that have shown that when an artery is exposed to radiation, inflammation appears in the arterial wall and can lead to the rupture of fatty deposits, which is a common cause of heart attacks in humans. This may, in part, explain the increased risk of heart problems following radiation therapy to the chest in patients who likely have such fatty deposits in their coronary arteries.


'/>"/>

Contact: Wendy Stokes
wstokes@hematology.org
202-552-4927
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Lymphoma Survivors Often Miss Out on Follow-Up
2. Study shows Hodgkin lymphoma survivors lack post-treatment screening for other cancers
3. Study identifies promising treatment for aggressive lymphoma
4. Lifestyle Affects Survival in Non-Hodgkins Lymphoma
5. Lifestyle factors significantly impact survival of non-Hodgkins lymphoma patients, study finds
6. Scott & White Healthcare clinical trials target lymphoma, leukemia
7. Vitamin K may protect against developing non-Hodgkins lymphoma, say Mayo Clinic researchers
8. New class of drug kills lymphoma cells
9. Vitamin D Linked to Survival in Lymphoma Patients
10. A new target for lymphoma therapy
11. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... ... Journal of Pain Research has seen a significant increase in its ranking ... Scopus database (Elsevier B.V.) and is a measure of a journal's impact. It takes ... year period and also the importance of the journals where the citations came from. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... will discuss how to improve care by making data on heart procedures public ... The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease ...
(Date:2/11/2016)... NJ (PRWEB) , ... February 11, 2016 , ... ... the call for nominations seeking candidates for the Board of Commissioners. Individuals interested ... passion, skills and experience with diversity of clinical practice settings and across allied ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, ... 334 spine surgeons to know in 2016 . The list consists of spine surgeons ... surgery. , Dr. Corenman understands the importance of clinical excellence; he has been ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the ... of DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel ... list. The panel’s goal is to recognize and promote technology entrepreneurship. , The ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Scientists from Silicon Biosystems Menarini today ... door to genetic analysis of previously preserved tumor ... isolate with 100 percent purity. Utilizing the com­pany,s ... various stages of development, the researchers were able ... are clinically relevant, and may change the way ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
(Date:2/11/2016)... 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced ... a Controlled Equity Offering SM Sales Agreement with ... Macaluso , Chairman and CEO, stated "During our most ... currently raising money and that we have enough money ... still complete all of our current objectives and nothing ...
Breaking Medicine Technology: